Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pirtobrutinib and Venetoclax in CLL/SLL Resistant to Covalent BTKi
NCT06466122Phase 2Recruiting
- Start
- Nov 2024
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pirtobrutinib and venetoclax in chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). Primary endpoint: Rate of undetectable minimal residual disease. Started Nov 2024; status: recruiting.
02
Drugs
pirtobrutinibvenetoclax
03
Conditions
chronic lymphocytic leukemia (CLL)small lymphocytic lymphoma (SLL)
Beyond the preview
Go deeper on NCT06466122.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06466122.